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Serum ferritin levels are a proxy measure of iron stores;
existing guidelines for managing anemia in hemodialysis
patients suggest that serum ferritin concentrations should be
maintained at 4200 ng/ml. The KDOQI recommendations
further state there is insufficient evidence advocating routine
intravenous iron when ferritin levels exceed 500 ng/ml. Here
we determined the interassay differences and short-term
intraindividual variability of serum ferritin measurements in
patients on chronic hemodialysis to illustrate how these
variances may affect treatment decisions. Intermethod
variations of up to 150 ng/ml were found comparing six
commonly used ferritin assays that evaluated thirteen pools
of serum from hemodialysis and nonhemodialysis patients.
The intraindividual variability for ferritin in 60 stable
hemodialysis patients ranged between 2–62% measured over
an initial two-week period and from 3–52% when factored
over a six-week period. Our results suggests that single
serum ferritin values should not be used to guide clinical
decisions regarding treatment of chronic hemodialysis
patients with intravenous iron due to significant analytical
and intraindividual variability.
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Patients on chronic hemodialysis undergo routine laboratory
assessment of their hematologic and iron status that includes
measurement of serum ferritin and transferrin saturation.1–3
For chronic kidney disease (CKD) patients on hemodialysis
taking erythropoiesis-stimulating agents, the 2006 National
Kidney Foundation Kidney Disease Outcomes Quality
Initiative (KDOQI) Guidelines and Clinical Practice Recom-
mendations suggest that iron status be assessed at least once
every 3 months. The KDOQI practice recommendations
further specify that ferritin concentrations should be
maintained at X200 ng/ml and that there is insufficient
evidence to routinely recommend iron supplementation
when ferritin is 4500 ng/ml.4 The utility of any specific
upper limit for ferritin has been a matter of debate.5,6 The
KDOQI statements indicate a ferritin of 500 ng/ml should
not serve as an upper limit but a clinical decision point. Both
older7,8 and recent studies 9,10 show that dialysis patients with
elevated serum ferritin can respond to i.v. iron therapy with
an increased hemoglobin and decreased epoetin require-
ments.11,12 Although higher ferritin is thought to reflect more
storage iron, these and other studies have found ferritin over
a broad range of values to be a poor predictor of
responsiveness to i.v. iron and the reasons for this are
unclear.9,11,12
There are many well-characterized caveats for not using
serum ferritin as a proxy for iron stores.13 Ferritin is an acute
phase reactant that is elevated independently of iron stores in
infection, inflammation, malignancy, and chronic disease.
This can limit the utility of serum ferritin for the assessment
of iron deficiency or overload in disease states such as CKD.14
Further, biological variability of serum ferritin in healthy
subjects is substantial with a day-to-day intraindividual
coefficient of variation (standard deviation divided by the
mean; intraindividual coefficients of variation (CVI)) of 15%
in males to 27% in females.15 Long-term month-to-month
CVI in patients on chronic hemodialysis is greater and ranges
from 23 to 43%.3
Analytical variability in the measurement of serum ferritin
also appears to be significant. Data from College of American
Pathology proficiency testing programs of ferritin immuno-
assay methods with 1925 participating laboratories show that
the interassay coefficients of variation (CV) from all methods
and all labs is 11% and that the difference in ferritin values
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between some methods was as much as 54%.16 Taken
together, it is important to understand the magnitude and
sources of variability in serum ferritin concentrations in
dialysis patients. The objectives of this study were to
investigate intermethod differences in ferritin values among
the six most common16 ferritin immunoassays and to
evaluate the short-term intraindividual variability of serum
ferritin concentrations in patients on chronic hemodialysis.
RESULTS
Intermethod difference in ferritin values
Absolute difference in ferritin methods was as much as
150 ng/ml between some methods and when compared with
the most commonly used method (Siemens Centaur) all but
the Siemens Dimension method produced significantly
different ferritin values for these serum pools (Figure 1).
The largest absolute bias between any two methods was
between the Abbott and Beckman-Coulter methods (Fig-
ure 1). With the Siemens (Bayer) Centaur as the predicate
method, proportional biases (slope) observed for the other
five methods were 0.87–1.18 (Table 1). Correlation coeffi-
cients for all of the regression analyses wereX0.98. There was
no significant difference in intermethod differences in ferritin
values between the pools prepared from nondialysis or from
dialysis patients (Figure 1). These methods represent the six
most common ferritin methods and account for about 70%
of all laboratories participating in the College of American
Pathology proficiency testing program.16 Routine quality
control data for these methods showed total analytic
imprecision to range from 2.9 to 8.4% CVA (data not
shown). Table 2 shows predicted serum ferritin values that
each assay might be expected to produce using the observed
Deming linear regression relationships between assays if the
Siemens (Bayer) Centaur ferritin assay returned a result equal
to the current and historical (2001) KDOQI cutoff values of
200, 500, and 800 ng/ml.
Intraindividual variability
The characteristics and baseline clinical laboratory results of
the 60 patients are summarized in Table 3. The gender and
race distribution are consistent with the patient demo-
graphics in our urban hemodialysis centers. One patient in
group 2 had a single ferritin concentration of 8710 ng/ml
in the fourth week that was confirmed three times and
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Figure 1 | Bland–Altman difference plots. The horizontal axes reflect the average serum ferritin value (units ng/ml) obtained with the
method shown and the predicate method. The vertical axes reflect the serum ferritin value (units ng/ml) of the method shown minus the
value obtained with the predicate method. The predicate method for panels a–e is the Siemens Centaur method; the predicate method for
panel f is the Beckman Access method. Closed circles: pool samples from nonhemodialysis patients. Open circles: pool samples from
hemodialysis patients. Thin solid line: mean difference of method shown minus predicate. Dotted horizontal lines: ±2 s.d. P values of
difference were o0.001 for panels a, b, d, and f, 0.011 for panel e, and 0.21 for panel c.
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subsequently excluded as an outlier from all data analyses.
Over 2 weeks (n¼ 4 samples/subject), the median CVI for all
60 subjects was 9.1% (interquartile range (IQR) 5.8, 13.9%)
(Table 4). For the 6-week period (n¼ 8 samples/subject), the
median CVI for the 60 subjects was 10.6% (IQR 8.2, 17.3%)
(Table 5). There was no statistical difference in 2- and 6-week
CVIs either within or between the three groups (all P values
X0.14) (Table 5). Differences between the highest and lowest
ferritin for any one patient during this 6-week period could
be substantial (Figure 2).
Six-week CVI did not correlate with weekly erythropoietin
(EPO) dose (correlation coefficient 0.12; 95% confidence
interval 0.13 to 0.37). Mean weekly i.v. iron and EPO
dosage was not significantly different between any two
groups, although there was an insignificant (P¼ 0.3) inverse
relationship between EPO doses of groups 1 and 3 (Table 1).
The 2- and 6-week mean CVIs of serum ferritin were also not
significantly different between patients given i.v. iron
(n¼ 51) and those not receiving iron (n¼ 9) (P values 0.35
and 0.37, respectively). In those patients receiving iron, the
weekly iron dose did not correlate with the 6-week serum
ferritin CVI (r¼0.18, P¼ 0.17). Finally, males (n¼ 25) had
a slightly higher mean 6-week CVI (16.0% ± 11.6%) than
females (n¼ 35) (11.7±5.6%), which neared statistical
significance (P¼ 0.09). Males also had a 4.3% higher mean
2-week CVI (P¼ 0.14).
The initial mean hemoglobin concentrations were similar
among groups 1, 2, and 3 (Table 3). At week 6, patients in
group 1 had a statistically significant decline in hemoglobin
from week 1 (mean decrease 0.72 g/100 ml, P¼ 0.047),
although this was not significantly different from the week 6
mean hemoglobin concentrations in group 2 (11.2 g/100 ml,
P¼ 0.10) and group 3 (11.6 g/100 ml, P¼ 0.11). There were
two significant adverse events (atrial fibrillation and a fall)
over the course of the study, neither of which met exclusion
criteria.
DISCUSSION
This study demonstrates multiple sources for variability of
serum ferritin results. The intermethod average differences in
ferritin values between the six most common serum ferritin
immunoassays is as high as 150 mg/100 ml (Figure 1). These
results are consistent with current proficiency testing data16
as well as a previous study that compared different ferritin
methods using pooled human sera.17 In addition to routine
measurement at the dialysis facility’s designated clinical
laboratory, iron status testing may be performed at the
hospital laboratory during illnesses, or at other clinical
laboratories as deemed by insurance providers or consultants.
When this occurs, a change in a patient’s ferritin may be due
simply to it being performed with a different method rather
than a change in iron status. When set cutpoints are stated in
clinical guidelines, it is important that all available commer-
cial methods be in agreement across the entire range of
expected values. This is clearly not the case for the six most
common ferritin methods. Of the 479 patient samples
analyzed using the Siemens Centaur method in this study,
14 were below 200 ng/ml, 120 were between 200 and 499 ng/
ml, and 345 were 4500 ng/ml. Using the linear regression
equations to predict values by other methods, it could be
expected that with the Roche method there would be four
samples with valueso200 ng/ml, 94 between 200 and 499 ng/ml,
and 380 4500 ng/ml. With the Beckman method it could be
expected that 20 of these samples would be o200 ng/ml, 164
between 200 and 499, and 294 4500 ng/ml.
Additional uncertainty is introduced into ferritin mea-
surements by within laboratory analytic imprecision which
for the methods used here ranges from 2.9 to 8.4% CVA.
Finally, biologic or intraindividual variation of serum ferritin
is considerable (IQR of 8–17%) in these stable dialysis
patients over the 2 and 6 week periods we examined and
might be expected to be even greater if measured quarterly,3
Table 1 | Relationships between different ferritin immunoassays
Ferritin method
x y
Deming regression
equation
95% confidence
interval of slope
95% confidence
interval of intercept
Mean %
differencea Pb
Siemens Centaur Beckman y=0.87x+4.1 (0.80; 0.95) (50.6; 58.8) 12.8 o0.001
Siemens Centaur Ortho Vitros Eci y=0.89x–6.2 (0.84; 0.95) (46.1; 33.8) 13.4 o0.001
Siemens Centaur Siemens Dimension RxL y=0.91x+30.7 (0.80; 1.00) (47.9; 109.3) 1.7 0.50
Siemens Centaur Roche Elecsys y=1.10x+27.8 (1.03; 1.17) (22.4; 78.0) 15.1 o0.001
Siemens Centaur Abbott Architect y=1.18x42.0 (1.05; 1.31) (133.3; 49.2) 8.8 0.002
Beckman Access Abbott Architect y=1.36x48.2 (1.21; 1.51) (142.2; 45.8) 21.6 o0.001
aMean % difference calculated by method of Bland and Altman.32
bP calculated from two-tailed t-test with null hypothesis that the mean percent difference is equal to zero.
Table 2 | Predicted values obtained with each assay at current
and historical KDOQI cutoffsa
Assay
Ferritin
(ng/ml)
Ferritin
(ng/ml)
Ferritin
(ng/ml)
Siemens Centaur 200 500 800
Beckman Access 178 439 700
Ortho Vitros Eci 172 439 706
Siemens Dimension RxL 212 486 759
Roche Elecsys 2010 194 548 902
Abbott Architect 224 632 1040
KDOQI, National Kidney Foundation Kidney Disease Outcomes Quality Initiative.
aValues shown are the predicted values from the Deming regression equations in
Table 1, assuming values of 200, 500, and 800 were obtained using the Siemens
Centaur method.
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or in unstable patients. Previous long-term measurements of
CVI for ferritin in patients on chronic hemodialysis ranged
from 23 to 43%, with the greatest CVI occurring when serum
ferritin is measured immediately after administration of i.v.
iron.3 Our results examined shorter time periods, limited
iron administration to low and constant doses, and measured
ferritin only several days after an iron dose. Consequently,
our CVI results might be expected to be somewhat lower.
Although ferritin is a marker of iron status, it is also an
acute phase reactant and consequently influenced by
inflammation, infection, and malignancy. Nutritional status18
and liver disease19 can also affect serum ferritin levels. We
selected patients that were clinically stable and excluded those
with known cancer, autoimmune, or liver disease, which
again likely diminished the intraindividual variability in
ferritin we observed.
In subjects with normal renal function, the mean CVI for
ferritin is also high (13% in males versus 26% in females) and
similar to our results with stable hemodialysis patients.15 We
did not observe a significant difference between genders
among patients on chronic hemodialysis, which likely reflects
the postmenopausal status of our female patients. Serum
ferritin is affected by the dose of i.v. iron administered, and
possibly by the rate of infusion or type of i.v. iron
product.20,21 However, we did not observe any impact of
i.v. iron doses on ferritin CV1 consistent with the short half-
lives of these products . We also saw no impact of EPO dosing
on CV1 in these stable patients.
The impact of intraindividual variation on possible
management decisions can be seen by the fact that among
the 20 stable patients selected for initial ferritin values
between 200 and 500 ng/ml, 12 (60%) had at least one value
above (eight) or below (four) this targeted range. A statistical
approach that encompasses intraindividual variability (CV
and analytic imprecision to determine whether the difference
between consecutive results for a single analyte is clinically
significant is the reference change value or critical differ-
ence.22 Reference change value takes into account the analytic
variability (CVA) and biologic variability (CVI) and for 95%
confidence that a physiologic change has occurred it is
calculated reference change value¼ 2.77 (CVA2þCVI2)
(1/2). Using a typical CVA of 4% seen with these six methods
and the observed median CVI of 11% for these 60 CKD
patients, the critical difference for ferritin is 32%. Thus, if an
initial ferritin value is 500 ng/ml, it must change by at least
160 ng/ml in the subsequent value to be 95% confident that it
is a true physiologic change. This approach does not take into
account the between method differences we found. Thus, the
200–500 ng/ml target for CKD patients is a fairly narrow
range when both analytic and biologic variability are taken
into account and only very large changes in subsequent
ferritin values can be considered to be physiologically
significant.
Intermethod bias among immunoassay methods has also
been observed for parathyroid hormone (PTH),23 which is an
important tool in KDOQI guidelines for managing bone
Table 5 | Individual 6-week (n=8) coefficients of variation
(CVI, %)
All patients Group 1 Group 2 Group 3
Number 60 20 20 20
Range 2.8–51.6 4.7–51.6 2.8–32.0 5.5–39.2
Median 10.6 12.1 8.8 11.5
IQR 8.2–17.3 9.0–18.6 6.6–12.6 9.4–18.9
Arithmetic mean (s.d.) 13.5 (8.8) 15.0 (10.4) 10.7 (6.6) 14.8 (8.7)
Table 3 | Baseline and end-of-study demographic and biochemical characteristics of patient groups (mean (s.d.))
Parameter All (n=60) Group 1 Group 2 Group 3
Age (year) 57.8 (12.4) 59.2 (12.5) 58.5 (14.7) 55.7 (9.9)
Men (n (%)) 25 (42) 8 (40) 10 (50) 7 (35)
African-American (n (%)) 53 (88) 14 (70) 19 (95) 20 (100)
Hemoglobin (g/100 ml) 11.6 (0.9) 11.8 (0.8) 11.5 (0.7) 11.6 (1.1)
Post-study hemoglobin (g/100 ml) 11.3 (1.2) 11.0 (1.3)a 11.2 (0.6) 11.5 (1.5)
Mean pre-study ferritin (ng/ml)b 392 (88) 668 (80) 1077 (306)
Mean initial ferritin (ng/ml)c 386 (120) 642 (85) 999 (266)
Mean end-study ferritin (ng/ml)d 376 (153) 645 (133) 898 ((283)
Mean EPO dose/week (IU) 14 397 (16 121) 18 906 (22 921) 14 340 (10 804) 9945 (11 077)
Mean i.v. iron dose (mg/week) 32.0 (20.2) 26.6 (16.8) 33.8 (14.7) 35.6 (26.8)
Ferrlecit/venofer/none 37/14/9 8/8/4 19/0/1 10/6/4
an=19.
bPre-study serum ferritin used to stratify patients into study groups, analyzed by Spectra Laboratories (Fremont, CA, USA) on the Siemens (Bayer) Centaur.
cSerum ferritin concentration of the first patient sample, analyzed on the Siemens (Bayer) Centaur.
dSerum ferritin concentration of the final patient sample, analyzed on the Siemens (Bayer) Centaur.
Table 4 | Individual 2-week (n=4) coefficients of variation
(CVI, %)
All patients Group 1a Group 2 Group 3
Number 60 20 20 20
Range 2.1–62.0 2.5–62.0 2.1–37.4 2.2–31.4
Median 9.1 10.3 7.7 10.4
IQR 5.8–13.9 5.8–15.2 5.1–9.2 6.4–14.1
Arithmetic mean (s.d.) 11.4 (9.7) 12.7 (12.6) 9.5 (7.8) 12.1 (8.2)
aGroups 1, 2, and 3 defined by baseline ferritin of 200–500, 500–800, and 4800 ng/ml,
respectively.
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homeostasis in patients with CKD.24 The variability between
PTH assays is similar to our data for the most common
ferritin methods. However, unlike PTH, there has been no
dominant ‘gold standard’ method on which guideline values
were mainly based, and most nephrology publications fail to
identify the ferritin immunoassay method, to indicate
analytic imprecision, or acknowledge biologic variabil-
ity.10–12,25 As with ferritin, the utility of the recommended
PTH target range is now being questioned.5
The multiple sources of variability in ferritin values we
document here raise questions about the value of a narrow
target for ferritin or reliance on a single serum ferritin
concentration to make clinical decisions. In the future when
clinical guidelines are developed that rely on poorly
standardized immunoassay values such as ferritin and PTH,
experts in laboratory medicine should have input as such
individuals are aware of the vagaries and limitations of these
assays.
The 1997 and 2001 KDOQI anemia guidelines recom-
mended that dialysis patients maintain serum ferritin above
100 ng/ml with i.v. iron, and to avoid iron therapy if the
ferritin was 4800 ng/ml or transferrin saturation (TSAT)
450%. In 2006, a new KDOQI statement recommended
maintaining ferritin above 200 ng/ml in hemodialysis patients
via i.v. iron,4 and noted ‘there is insufficient evidence to
recommend routine administration of i.v. iron if serum
ferritin level is greater than 500 ng/ml.’4 The workgroup
acknowledged the limited data available to reach their
recommendations.4 The magnitude of analytic and biologic
variability in serum ferritin concentrations we observed
could easily move the average hemodialysis patient into a
serum ferritin range that would potentially alter i.v. iron
management based on the present KDOQI recommenda-
tions. Indeed, different ferritin assays may result in systematic
over- or undertreatment of this population even if there was
very little biologic variability.
A narrow ferritin ‘target’ relies on accurate and repro-
ducible ferritin measurements. Recently, an editorial by a
KDOQI workgroup member emphasized that their ferritin
recommendation of 500 ng/ml should not be construed as a
strict stopping point for i.v. iron therapy, but rather ‘given
the lack of evidence, and problems with serum ferritin as an
analyte’ clinical judgment should be used to determine the
need and goals for iron therapy.26 That viewpoint is
supported by our data and recent randomized trial data
showing efficacy and short-term safety for i.v. iron when
ferritin is 4500 ng/ml.9,10,27
Other tests have been suggested to guide iron therapy
decisions. TSAT has a high CVI, similar to ferritin.
3 KDOQI
recommends maintaining TSAT 420%,4 although TSAT was
not predictive of a hematological response to i.v. iron in
dialysis patients or CKD patients in recent randomized trials
which included patients with TSAT up to 25%.9,10,28 Besarab
et al.7 found iron treatment to target TSAT to 30–50%
resulted in greater epoetin sparing than a TSAT target of
20–30%. Reticulocyte hemoglobin concentration (CHr) and
percentage of hypochromic red blood cells (PHRCs) have
also been suggested as tests. KDOQI recommends iron
treatment when CHr is o29 pg. Tessitore et al. found CHr
o29 pg, PHRC 46%, had discriminative value in detecting
responders to i.v. iron.29 Fishbane et al.30 found CHro29 pg
was a significantly better guide to i.v. iron requirements than
ferritin o100 ng/ml in a 6-month study. However, two 6-
week trials found those with CHr o29 pg were less likely to
respond to i.v. iron 10,28 and concluded CHr should not be
employed as a diagnostic test. The European Best Practices
workgroup states patients with PHRC is 46% are most likely
to respond to i.v. iron.31 PHRCo2.5% is considered normal.
However, PHRC must be measured on a sample less than 4 h
old, as cell swelling leads to erroneous increases in PHRC.
Consequently, this test is unavailable where samples are
shipped to central laboratories.
Taken together, our results suggest that serum ferritin
concentration should be interpreted with caution in patients
on chronic hemodialysis. General trends in ferritin determi-
nations over time and changes in erythropoiesis stimulating
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Figure 2 | Range of serum ferritin values for individual patients expressed as the difference between each subject’s individual
maximum and minimum serum ferritin values over 6 weeks (n=20 for each group). Solid line: median, dashed line: mean, gray box:
interquartile range, whiskers: 10th/90th percentiles, and closed circles: values outside the 10th and 90th percentiles.
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agent doses, rather than specific ferritin numerical cut-offs,
may be better determinants of the adequacy of iron therapy.
More reliable and stable laboratory tests of iron status in
patients on chronic hemodialysis are also needed.
MATERIALS AND METHODS
Study design
This study was approved by the Human Studies Committee at
Washington University. This study consisted of two components:
determination of intermethod differences in ferritin values among
the six ferritin immunoassays and measurement of intraindividual
variability of ferritin over 2 and 6 weeks in stable chronic
hemodialysis patients.
Part I. Bias between ferritin methods
A total of 13 serum pools with ferritin values spanning the range of
50–1200 ng/ml were analyzed with the Siemens Healthcare Diag-
nostics (formerly Bayer Diagnostics) Centaur, Siemens Healthcare
Diagnostics (formerly Dade Behring) Dimension RxL, Abbott
Diagnostics Architect, Roche Diagnostics Elecsys, Beckman-Coulter
Access, and Ortho Clinical Diagnostics ECi methods. Table S1 shows
expected values for each method. A total of 10 serum pools of
12–15 ml each were prepared using excess residual serum from
nonrenal disease patients submitted to the Barnes-Jewish laboratory
for routine, physician ordered serum ferritin. Each pool was prepared
by combining 12–15 different patient samples having similar ferritin
values in increments of approximately 100 ng/ml. The remaining
three serum pools were prepared in a similar manner using residual
serum from the 60 dialysis patients described below. Serum pools
were analyzed in a single batch on each of the above instruments
together with the institutions’ quality control material according to
manufacturers’ recommendations. Expected values from the package
inserts for each of these methods is provided as Table S1.
Part II. Intraindividual variability of serum ferritin
concentrations in stable hemodialysis patients
Eight serum samples were obtained from 60 stable hemodialysis
patients at their routine hemodialysis sessions. Samples were
obtained twice a week for 2 weeks and then once a week for the
next 4 weeks. Eligible patients provided informed consent at one of
our two academic urban dialysis facilities, and were 418 years of
age, not pregnant, on chronic hemodialysis three times per week,
had missed no more than one hemodialysis session in the last 4
weeks, and had a baseline hemoglobin 410 g/100 ml. Patients were
receiving either no iron or maintenance i.v. iron (defined as
p125 mg/week of ferric gluconate or iron sucrose) for the previous
4 weeks. None had a change in iron dosing over the course of the
study. No patients were receiving oral iron. All patients were
receiving epoetin alfa (Epogen; Amgen; Thousand Oaks, CA, USA).
Exclusion criteria were active bleeding in the previous 8 weeks,
transfusion within the last 12 weeks, any hematological disorder
other than anemia, cancer, Gaucher disease, acute or chronic liver
disease, HIV positive, a history of autoimmune disease, antibiotics
in the last month, or enrollment in another study.
Three groups of 20 patients were recruited based on their most
recent serum ferritin concentration (obtained within 30 days of
entering the study and analyzed by Spectra Laboratories (Fremont,
CA, USA) per standard protocol of the two dialysis centers: group 1,
initial ferritin 200–500 ng/ml; group 2, initial ferritin 500–800 ng/ml;
and group 3, initial ferritin 800–1200 ng/ml. All patients completed
the study. One patient in group 1 had a renal transplant immediately
following week 6 testing and did not have a post-study hemoglobin
value available. Blood was obtained immediately before adminis-
tration of any weekly i.v. iron to minimize the contribution of i.v.
iron to short-term intraindividual variability in serum ferritin.
Samples were processed within 1 h of drawing and stored at 80 1C.
All eight samples from any one patient were analyzed as a single
batch by the Siemens (Bayer) Centaur method at the Barnes Jewish
Hospital Clinical Chemistry laboratory to minimize analytic
variability.
STATISTICAL ANALYSES
Differences in ferritin values between methods was assessed
by Bland–Altman difference plots32 and by Deming linear
regression analysis33 with the Siemens (Bayer) Centaur
method as the predicate method. This method was chosen
as the predicate method because it is the most commonly
used method in the United States.16 Short-term variability in
serum ferritin was summarized as CVI and IQRs. Day to day
(over 2 weeks) and week to week (over 6 weeks) CVIs were
calculated for each volunteer as well as the mean, median,
and range of CVIs for each group. Correlation coefficients
were used to assess associations between variables. Paired
t-tests were used to compare pre-study and post-study
hemoglobin and ferritin concentrations. Two-sample t-tests
were used to compare other unpaired groups. A P-value of
less than 0.05 was considered statistically significant. All
calculations were performed using SYSTAT 12, SYSTAT Inc.
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